|
Volumn 167, Issue 7, 2016, Pages 1669-
|
IL-17 Blockade in Psoriasis
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIPSORIASIS AGENT;
CYTOKINE RECEPTOR ANTAGONIST;
HETERODIMER;
INTERLEUKIN 17;
INTERLEUKIN 17 INHIBITOR;
INTERLEUKIN 17 RECEPTOR;
INTERLEUKIN 17A RECEPTOR;
INTERLEUKIN 17C RECEPTOR;
IXEKIZUMAB;
SECUKINUMAB;
UNCLASSIFIED DRUG;
IL17A PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
CD4+ T LYMPHOCYTE;
CD8+ T LYMPHOCYTE;
CYTOKINE PRODUCTION;
DRUG TARGETING;
EPITHELIUM CELL;
GAMMA DELTA T LYMPHOCYTE;
HUMAN;
LYMPHOID CELL;
LYMPHOID TISSUE INDUCER CELL;
MAST CELL;
MESENCHYME CELL;
NATURAL KILLER T CELL;
NEUTROPHIL;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PSORIASIS;
SHORT SURVEY;
SIGNAL TRANSDUCTION;
TH17 CELL;
UPREGULATION;
ANTAGONISTS AND INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
HUMANS;
INTERLEUKIN-17;
PSORIASIS;
|
EID: 85006307134
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2016.11.044 Document Type: Short Survey |
Times cited : (46)
|
References (10)
|